Compliance with antimicrobial therapy for buruli ulcer.

Klis, S; Kingma, R; Tuah, W; Stienstra, Y; van der Werf, T S

Klis, S; Kingma, R; Tuah, W; Stienstra, Y; van der Werf, T S.

Afiliación

Klis S; Department of Internal Medicine, Infectious Disease Service, University Medical Center Groningen, Groningen University, Groningen, The Netherlands s.klis@umcg.nl.
Kingma R; Department of Internal Medicine, Infectious Disease Service, University Medical Center Groningen, Groningen University, Groningen, The Netherlands.
Tuah W; Nkawie-Toase Government Hospital, Nkawie, Ghana.
Stienstra Y; Department of Internal Medicine, Infectious Disease Service, University Medical Center Groningen, Groningen University, Groningen, The Netherlands.
van der Werf TS; Department of Internal Medicine, Infectious Disease Service, University Medical Center Groningen, Groningen University, Groningen, The Netherlands Department of Pulmonary Medicine and Tuberculosis, University Medical Center Groningen, Groningen, The Netherlands.

Antimicrob Agents Chemother ; 58(10): 6340, 2014 Oct.

Article en En | MEDLINE | ID: mdl-25225342

Asunto(s)

Antibacterianos/uso terapéutico; Úlcera de Buruli/tratamiento farmacológico; Claritromicina/uso terapéutico; Mycobacterium ulcerans/efectos de los fármacos; Rifampin/uso terapéutico; Estreptomicina/uso terapéutico; Femenino; Humanos

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Rifampin / Estreptomicina / Claritromicina / Mycobacterium ulcerans / Úlcera de Buruli / Antibacterianos Límite: Female / Humans Idioma: En Año: 2014 Tipo del documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google